June 9, 2025- In a new study, Mayo Clinic researchers confirmed the accuracy of an FDA-approved blood test that can be used at outpatient memory clinics to diagnose the disease in patients with a range of cognitive impairment. Standard ways of measuring the buildup of toxic proteins in the brain that indicate Alzheimer’s disease include positron emission tomography, or PET scans, and spinal taps. But these tests can be expensive and invasive, according to Mayo Clinic. More accessible, non-invasive and cost-effective biomarkers — measurable indicators of a disease — are needed to improve diagnoses broadly in clinical settings. The findings are published in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association.